CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $84.00 in a report issued on Thursday morning, Benzinga reports. Citigroup currently has a buy rating on the stock. Several other research firms have also recently weighed in on CRSP. TheStreet upgraded shares of CRISPR Therapeutics from a d+ […]